Sociedad Americana de Hirudoterapia

Medicinal leeches and the microsurgeon: a four-year study, clinical series and risk benefit review

Whitaker IS, Josty IC, Hawkins S, Azzopardi E, Naderi N, Graf J, Damaris L, Lineaweaver WC, Kon M (2011) · Microsurgery · n=35

Detalle de evidencia de RCTReferencia del ensayo
GRADE bajaCohorte / serie de casos
Tamaño de muestra de este ensayo en comparación con otros ensayos de venous-congestion-flapMarquard JM 20251215Bishop JL 2023843Doğan S 2024570Troeltzsch M 2016330Kucur C 2015260Wang ZD 2022210Lehnhardt M 202196Kruer RM 201459Mozafari N 201056Whitaker IS 201135
Este ensayo (destacado) por tamaño de muestra junto a otros ensayos indexados de venous-congestion-flap. Los ensayos más grandes generalmente tienen mayor peso estadístico.

Perfil del estudio

Diseño
single-center, retrospective 4-year clinical series and risk-benefit review (Welsh Centre for Burns and Plastic Surgery, Morriston Hospital, Swansea, UK)
Tamaño de la muestra (n)
35
Intervención
Hirudo medicinalis leeches prescribed for venous congestion in pedicled flaps and digit/limb replantations between July 2004 and 2008 (mean age 49.3 years, range 2-98)
Comparador
Retrospective comparison of leech-treated cases with and without prophylactic antibiotic coverage (no parallel non-leech arm)
Punto final primario
Tissue salvage rate at 30 days; secondary endpoints: infection rate (Aeromonas), transfusion requirement, antibiotic prophylaxis stratification
Resultado primario
40% (14/35) of cases salvaged in entirety; 20% (7/35) with 80% or more salvage; 5.7% (2/35) with 50-79% salvage; 2.9% (1/35) with less than 50% salvage; 31% (11/35) total tissue loss; infection rate 20% (7/35) overall and 14.2% (5/35) with Aeromonas; transfusion required in 34% (12/35), mean 2.8 units (range 2-5)
Duración del seguimiento
30 days post-procedure

Hallazgos clave

  • Largest published UK single-center microsurgery leech case series (n=35) at the time of publication
  • Infection rate 20% overall including 14.2% Aeromonas - higher than many German centers, reinforcing prophylactic-antibiotic case
  • Infection rate significantly higher in patients not receiving prophylactic antibiotics (Fisher exact test p=0.0005) - direct evidence supporting routine ciprofloxacin prophylaxis
  • 60% of cases achieved 80% or greater tissue salvage; 31% complete tissue loss reflects the salvage population (failed cases referred for leech therapy)
  • Identified species shift to Hirudo verbana as standard supplied leech and Aeromonas veronii as primary pathogen of concern

Limitaciones

  • Retrospective design - no randomization, no control arm
  • Small absolute sample size (n=35) over 4 years
  • Wide age range (2-98 years) with no stratified analysis
  • Single UK center - antibiotic and surgical practices may not generalize
  • Salvage population represents pre-selected failures of standard care, complicating outcome interpretation

Implicaciones clínicas

Whitaker 2011 is a foundational UK case series that established the empirical basis for routine antibiotic prophylaxis (ciprofloxacin) in leech therapy. The Fisher exact test result (p=0.0005) for prophylaxis-vs-no-prophylaxis is one of the strongest pieces of evidence in the literature supporting current guidelines that mandate antibiotic coverage for any leech application. The case series also documented the practical clinical experience of a UK academic plastic surgery unit, with realistic infection and transfusion rates that contrast with the lower numbers reported in highly-selected German RCTs. For clinicians, Whitaker 2011 should be read alongside Merlino 2020 (Italian flap-salvage RCT) and Elyassi 2014 (US digit replantation series) as part of the international risk-benefit literature.

Estudios relacionados

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.